Literature DB >> 22250847

The influence of neurocognitive impairment on HIV treatment outcomes among drug-involved people living with HIV/AIDS.

Ifeoma Ezeabogu1, Michael M Copenhaver, Jessica Potrepka.   

Abstract

Findings to date indicate that it is feasible to deliver a brief behavioral risk reduction/medication adherence group intervention to HIV-infected injection drug users in a community-based setting. HIV infection and substance abuse can result in neurocognitive impairment and this is directly relevant to intervention development, because a significant number of people living with HIV/AIDS have a positive history of substance abuse and being able to successfully participate in behavioral interventions often requires a relatively high level of cognitive performance. The aim of the current study was to evaluate if changes in information, motivation, and behavior skills with respect to medication adherence, sex- and drug-risk behavior outcomes from baseline to post-intervention are predicted by cognitive impairment following the brief four-session Holistic Health for HIV intervention for HIV-infected Drug Users (3H+). Significant associations were found between change in motivation and certain neurocognitive performance domains. Findings suggest that it may be helpful to specifically tailor such behavioral interventions to accommodate cognitive impairment.

Entities:  

Mesh:

Year:  2012        PMID: 22250847      PMCID: PMC3294373          DOI: 10.1080/09540121.2011.608794

Source DB:  PubMed          Journal:  AIDS Care        ISSN: 0954-0121


  27 in total

1.  As HIV spreads among injection drug users, treatment lags behind.

Authors: 
Journal:  AIDS Alert       Date:  1998-10

Review 2.  Intervening effectively with drug abusers infected with HIV: taking into account the potential for cognitive impairment.

Authors:  Michael Copenhaver; S Kelly Avants; Lara A Warburton; Arthur Margolin
Journal:  J Psychoactive Drugs       Date:  2003 Apr-Jun

Review 3.  The relationship between neuropsychological functioning and HAART adherence in HIV-positive adults: a systematic review.

Authors:  Travis I Lovejoy; Julie A Suhr
Journal:  J Behav Med       Date:  2009-03-17

Review 4.  Neuropsychological consequences of HIV and substance abuse: a literature review and implications for treatment and future research.

Authors:  Lisa R Norman; Michael Basso; Anil Kumar; Robert Malow
Journal:  Curr Drug Abuse Rev       Date:  2009-05

5.  Empirical tests of an information-motivation-behavioral skills model of AIDS-preventive behavior with gay men and heterosexual university students.

Authors:  J D Fisher; W A Fisher; S S Williams; T E Malloy
Journal:  Health Psychol       Date:  1994-05       Impact factor: 4.267

Review 6.  HIV-1 infection and cognitive impairment in the cART era: a review.

Authors:  Judith Schouten; Paola Cinque; Magnus Gisslen; Peter Reiss; Peter Portegies
Journal:  AIDS       Date:  2011-03-13       Impact factor: 4.177

Review 7.  Human immunodeficiency virus-type 1 (HIV-1) and the brain.

Authors:  I Grant; R K Heaton
Journal:  J Consult Clin Psychol       Date:  1990-02

8.  Testing an optimized community-based human immunodeficiency virus (HIV) risk reduction and antiretroviral adherence intervention for HIV-infected injection drug users.

Authors:  Michael M Copenhaver; I-Ching Lee; Arthur Margolin; Robert D Bruce; Frederick L Altice
Journal:  Subst Abus       Date:  2011-01       Impact factor: 3.716

9.  Medication adherence in HIV-infected adults: effect of patient age, cognitive status, and substance abuse.

Authors:  Charles H Hinkin; David J Hardy; Karen I Mason; Steven A Castellon; Ramani S Durvasula; Mona N Lam; Marta Stefaniak
Journal:  AIDS       Date:  2004-01-01       Impact factor: 4.177

10.  Characteristics of prospective memory deficits in HIV-seropositive substance-dependent individuals: preliminary observations.

Authors:  Eileen M Martin; Heather Nixon; David L Pitrak; William Weddington; Niles A Rains; Gerald Nunnally; Silvana Grbesic; Raul Gonzalez; Joanna Jacobus; Antoine Bechara
Journal:  J Clin Exp Neuropsychol       Date:  2007-07       Impact factor: 2.475

View more
  15 in total

1.  Rationale and design of an integrated bio-behavioral approach to improve adherence to pre-exposure prophylaxis and HIV risk reduction among opioid-dependent people who use drugs: The CHRP-BB study.

Authors:  Roman Shrestha; Frederick L Altice; Brian Sibilio; Jude Ssenyonjo; Michael M Copenhaver
Journal:  Contemp Clin Trials       Date:  2019-06-20       Impact factor: 2.226

2.  Psychosocial Correlates of Medication Adherence among HIV-Positive, Cognitively Impaired Individuals.

Authors:  Timothy J Arentsen; Stella Panos; April D Thames; J Natalie Arbid; Steven A Castellon; Charles H Hinkin
Journal:  J HIV AIDS Soc Serv       Date:  2016-09-23

3.  Modeling a Theory-Based Approach to Examine the Influence of Neurocognitive Impairment on HIV Risk Reduction Behaviors Among Drug Users in Treatment.

Authors:  Tania B Huedo-Medina; Roman Shrestha; Michael Copenhaver
Journal:  AIDS Behav       Date:  2016-08

4.  A Self-Report Measure to Detect Neurocognitive Impairment among Incarcerated People Living with HIV in Malaysian Context: An Exploratory Factor Analysis.

Authors:  Roman Shrestha; Damian Weikum; Michael Copenhaver; Frederick L Altice
Journal:  Int J Ment Health Addict       Date:  2017-04-03       Impact factor: 3.836

5.  An Exploratory Factor Analysis of a Brief Self-Report Scale to Detect Neurocognitive Impairment Among Participants Enrolled in Methadone Maintenance Therapy.

Authors:  Michael Copenhaver; Roman Shrestha; Jeffrey A Wickersham; Damian Weikum; Frederick L Altice
Journal:  J Subst Abuse Treat       Date:  2016-01-13

6.  Intent to Use Preexposure Prophylaxis (PrEP), HIV Risk Behaviors, and Self-Report Neurocognitive Symptoms by High-Risk Drug Users: A Mediation Analysis.

Authors:  Roman Shrestha; Pramila Karki; Tania B Huedo-Medina; Michael Copenhaver
Journal:  J Assoc Nurses AIDS Care       Date:  2017-04-19       Impact factor: 1.354

7.  Alcohol use disorders negatively influence antiretroviral medication adherence among men who have sex with men in Peru.

Authors:  Enrico G Ferro; Damian Weikum; Panagiotis Vagenas; Michael M Copenhaver; Pedro Gonzales; Jesus Peinado; Robinson Cabello; Javier R Lama; Jorge Sanchez; Frederick L Altice
Journal:  AIDS Care       Date:  2014-10-03

8.  Treatment Engagement Moderates the Effect of Neurocognitive Impairment on Antiretroviral Therapy Adherence in HIV-Infected Drug Users in Treatment.

Authors:  Roman Shrestha; Pramila Karki; Tania B Huedo-Medina; Michael Copenhaver
Journal:  J Assoc Nurses AIDS Care       Date:  2016-09-22       Impact factor: 1.354

9.  Willingness to Use Pre-Exposure Prophylaxis (PrEP): An Empirical Test of the Information-Motivation-Behavioral Skills (IMB) Model among High-Risk Drug Users in Treatment.

Authors:  Roman Shrestha; Frederick L Altice; Tania B Huedo-Medina; Pramila Karki; Michael Copenhaver
Journal:  AIDS Behav       Date:  2017-05

10.  Examining the Acceptability of mHealth Technology in HIV Prevention Among High-Risk Drug Users in Treatment.

Authors:  Roman Shrestha; Tania B Huedo-Medina; Frederick L Altice; Archana Krishnan; Michael Copenhaver
Journal:  AIDS Behav       Date:  2017-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.